Immune Therapeutics Inc (PK) (IMUN) Fundamentals

Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life-threatening diseases by stimulating or rebalancing the immune system. Our technology platform is based on two interrelated cytokine drug therapies-Low-Dose Naltrexone (LDN) and Methionine Enkephalin (MENK)-which work by triggering opioid receptors on immune cells to activate various cells of the immune system.
Share Info
Market Cap$ 967,428
Shares Authorized750,000,000
Shares Outstanding483,714
Shares Outstanding Date04/30/2021
Shareholder Count621
Shareholder Count Date04/15/2021
Float Date-
Short Interest39,991
Short Interest Date04/15/2021
Reporting Info
Reporting StatusSEC Reporting
Audit StatusYes
AuditorTurner, Stone & Company, L.L.P.
Auditor Address12700 Park Central Drive,
Suite 1400
Dallas, Texas 75251
Auditor Website
IR Firm-
IR Firm Address-
IR Firm Website-
Legal Counsel-
Legal Counsel Address-
Legal Counsel Website-
Fiscal Year End12/31
ADR Ratio-
Transfer AgentClearTrust, LLC
Transfer Agent Address16540 Pointe Village Dr.
Suite 205
Lutz, FL 33558
Depository Website
SHO Flag-
3210 Flag-
Company Info
Ticker SymbolUSOTC:IMUN
OTC Market TierPink Current
Security TypeCommon Stock
CIK Number0001559356
Address2431 Aloma Ave
Suite 124
Winter Park, Florida 32792
Fax #866-514-4807
SIC Code / Description2834 / Pharmaceutical preparations
Key ExecutivesCFO - Peter Aronstam
Dir. - Kevin Phelps
Dir. - Michael Sander
Chief Scientific Officer - Dr. Fengping Shan
Chairman - Dr. Roscoe Moore Jr.
Number of Employees4
Incorporation StateFlorida
Incorporation CountryUSA
Incorporation Year1993

Your Recent History
Immune The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.